A new study, published in Nature Communications, conducted by the University of Liverpool and the Johns Hopkins University School of Medicine highlights a new ‘long acting’ medicine for the prevention of malaria.
Every year, malaria afflicts hundreds of millions of people and kills hundreds of thousands of children. Despite considerable success in reducing the worldwide prevalence of malaria, its incidence in visitors to endemic areas has continued to rise steadily.
Currently, the best available prevention of malaria requires oral dosing of antimalarial tablets. Chronic oral dosing of these medicines has significant complications because healthy people need to strictly adhere to the medication in order for effective prophylaxis to occur.
The study, led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, aimed to utilise nanotechnology to improve the delivery of an existing antimalarial drug via a novel injectable format that can maintain blood concentration of the drug for weeks or months following a single dose.
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the diagnosis, prevention or treatment of disease in the human body.
Solid Drug Nanoparticles (SDNs) are a nanotechnology with favourable characteristics to enhance drug exposure and improve the treatment or prevention of several diseases, including HIV and malaria.
The Liverpool team have previously shown SDNs to be effective for oral delivery of drugs, but this is the first time they have shown benefits for a long-acting injectable (LAI) format. These particles have an approximate diameter that is 1/500th the width of a human hair, and once injected into the muscle, establish a drug depot that releases drug into the bloodstream over an extended period of time.
Through the use of this technology the trans-Atlantic research team developed an LAI version of a daily anti-malarial tablet (atovaquone) which provided prophylactic blood concentrations in mice for a period of 28 days. Moreover, mice injected with the nanomedicine were completely protected from the malaria parasite when exposed during this time, and since mice eliminate the drug much more rapidly in humans, a much longer duration of protection might be expected in people.
Impacting large numbers
Professor Rannard, said: “Although anti-malaria drugs exist they require individuals to take medication daily. Chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to preventative therapies.
“Our research seeks to remove the need for daily tablets and generate long-acting dosing technologies that may be able to provide therapeutic drug concentrations for months after a single administration. This would provide a clinically-relevant intervention that could readily impact large numbers of people and significantly prevent the transmission of malaria.”
Professor Owen, added “The ability of this nanomedicine to protect from infection by malaria may provide an additional tool in the global arsenal used to combat malaria in non-immune travellers and ultimately people who live in endemic areas of the world. Since atovaquone is already licenced for use in humans and the nanomedicine contains ingredients already used in other medicines, it could be enter clinical trials within a very short timescale”
“If other drugs can be manufactured in this way, in the longer term there is also potential for a long-acting combination therapy for malaria.”
The full study, entitled ‘Long-acting injectable atovaquone nanomedicines for malaria prophylaxis’, can be found here.
For further information about nano-medicine please listen to the University of Liverpool podcast featuring Professors Rannard and Owen which can be found here.
The Latest on: Solid Drug Nanoparticles
via Google News
The Latest on: Solid Drug Nanoparticles
- Downstream Processing of Complex Molecules, Pure and Simpleon September 3, 2019 at 4:44 am
Then, biopharmaceutical companies must capture that drug and ensure that it’s free of contamination ... magnetic biocompatible adsorbers offer a new alternative to classical solid-bed chromatography ...
- Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemiaon August 26, 2019 at 4:00 am
About Bio-Path Holdings, Inc. Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered ... a Phase ...
- Nanomaterials for Healthcare, Energy and Environmenton August 23, 2019 at 10:18 am
In this chapter, the use of nanomaterials in solid-phase extraction (SPE) protocols for water samples pretreatment for environmental monitoring is addressed. The most used nanomaterials, including ...
- Stimulus-responsive Macromolecules and Nanoparticles for Cancer Drug Deliveryon August 21, 2019 at 5:00 pm
Nanoparticles ... effect. Stimulus-responsive peptide and polymer vehicles can further enhance the efficacy of antitumor therapeutics compared with the administration of free drug by three mechanisms: ...
- Nanoparticles for Imaging and Treating Brain Canceron August 19, 2019 at 5:00 pm
Other carriers (polymers, dendrimers [among polymer-based carriers], nanogels, crosslinked bovine serum albumin 4-hydroxy-3-nitrophenylacetyl hapten, solid lipid nanoparticles [among nanosized drug ...
- Nanoscale 'glass' bottles could enable targeted drug deliveryon August 15, 2019 at 5:22 am
"The rest of the drug remains encapsulated by the solid fatty acids inside the bottles ... spheres out of polystyrene with a small gold nanoparticle embedded in its surface.
- Solid Gold Nanoparticles Boost Immune System: Studyon July 5, 2019 at 1:57 pm
‘Gold nanoparticles help to deliver various drugs directly into B lymphocytes. This aids to reduce unnecessary dosage and adverse effects.’ Responsible for the production of antibodies, B lymphocytes ...
- Pharmaceutical products made of solid goldon June 28, 2019 at 4:09 pm
Nanoparticles can form a protective vehicle for vaccines - or other drugs - to specifically deliver them where they can be most effective, while sparing other cells. This targeting also allows the use ...
- Medicines made of solid goldon June 28, 2019 at 3:30 pm
“Nanoparticles can form a protective vehicle for vaccines – or other drugs – to specifically deliver them where they can be most effective, while sparing other cells,” explains Carole Bourquin, a ...
via Bing News